🇺🇸 FDA
Patent

US 12201719

Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

granted A61KA61K2035/122A61K2039/505

Quick answer

US patent 12201719 (Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy) held by VACCINEX, INC. expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VACCINEX, INC.
Grant date
Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2035/122, A61K2039/505, A61K2239/31, A61K2239/49